Which treatment is indicated as first line for SARS-CoV-2 in high-risk patients?

Nirmatrelvir/ritonavir, commonly known as Paxlovid, is indicated as the first-line treatment for SARS-CoV-2 in high-risk patients due to its antiviral efficacy and favorable clinical outcomes. This oral medication works by inhibiting the replication of the virus, specifically targeting the protease enzyme, which is crucial for viral maturation and lifecycle.

The use of Paxlovid has been supported by clinical studies demonstrating its ability to significantly reduce the risk of hospitalization and severe disease progression in high-risk populations, such as the elderly or those with underlying health conditions. Additionally, its convenience as an oral treatment allows for easier administration compared to intravenous options, making it an accessible choice for patients who test positive for COVID-19.

On the other hand, Remdesivir is also an antiviral agent approved for COVID-19 but generally reserved for hospitalized patients due to its intravenous administration route and the need for monitoring. Supportive care is always important in the management of any viral illness, but it does not directly treat the virus itself, making it less effective as a first-line intervention. Hydroxychloroquine has been extensively studied and ultimately deemed ineffective for treating COVID-19, leading to its lack of recommendation in clinical guidelines.